AN2 Therapeutics(ANTX) - 2023 Q4 - Annual Results

Exhibit 99.1 AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents and investments of $134.5 million at December 31, 2023 Menlo Park, CA – March 28, 2024 – AN2 The ...